ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "outcomes"

  • Abstract Number: 2627 • 2018 ACR/ARHP Annual Meeting

    Not All Clinical Responders in SLE Are Equal: Comparison of Subcutaneous Belimumab + Standard of Care Responders to Placebo + Standard of Care Responders

    William Stohl1, Milena Kurtinecz2, Joe Eastman3, Vanessa Castellano4, Chrysa Mahoney4, Tania Gonzalez-Rivera2 and Bonnie Pobiner4, 1Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 2GlaxoSmithKline, Philadelphia, PA, 3GlaxoSmithKline (at the time of the study), Research Triangle Park, NC, 4GlaxoSmithKline, Research Triangle Park, NC

    Background/Purpose: To determine whether degree of response among responders to subcutaneous (SC) belimumab (BEL) + standard of care (SoC) is greater than that for responders…
  • Abstract Number: 1327 • 2018 ACR/ARHP Annual Meeting

    The Effect of Etoposide on Inducing Remission in Refractory Adult-Onset Still’s Disease: A Retrospective, Single-Center Study

    Haiting Wang1, Xiaodong Wang1, Ting Li1 and Shuang Ye2, 1Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2Rheumatology, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China

    Background/Purpose: Adult onset Still¡¯s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Macrophage activation syndrome (MAS) is a life-threatening complication and has been…
  • Abstract Number: 2663 • 2018 ACR/ARHP Annual Meeting

    Comparison of Clinical and Laboratory Profiles in 3575 Systemic Lupus Erythematosus Patients with and without Sjögren’s Syndrome: Data from the Spanish Society for Rheumatology Lupus Registry

    Juan Gabriel Ovalles-Bonilla1,2, Francisco Javier López Longo3, Iñigo Rúa-Figueroa4, María Galindo5, Jaime Calvo-Alén6, Juan Carlos Nieto2, Julia Martínez-Barrio3, Roberto González7, Belen Serrano8, Iustina Janta2, Carlos M Gonzalez9, Indalecio Monteagudo2 and JM Pego-Reigosa10, 1Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, 2Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 4Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, 5Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, 6Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain, 7Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, 8Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, 9Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 10Complexo Hospitalario Universitario de Vigo, Vigo, Spain

    Background/Purpose: The clinical coexistence of Systemic Lupus Erythematosus (SLE) and Sjögren's Syndrome (SS) was recognized in 1959. The prevalence of SS among patients with SLE…
  • Abstract Number: 1381 • 2018 ACR/ARHP Annual Meeting

    Association of Omeract Core Domains of Pain and Function with Patient Satisfaction after Total Joint Replacement

    Susan M. Goodman1, Bella Y. Mehta2, Lisa A. Mandl3, Jackie Szymonifka1, Mark P. Figgie4, Iris Navarro-Millán5, Mathias Bostrom6, Michael L. Parks7, Alexander McLawhorn8, Stephen Lyman7 and Jasvinder A. Singh9, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery/Weill Cornell Medicine/Mailman School of Public Health, New York, NY, 3Rheumatology, Hospital for Special Surgery, New York, NY, 4Surgery, Hospital for Special Surgery, New York, NY, 5Weill Cornell Medicine, New York, NY, 6Orthopaedic Surgery, Hospital for Special Surgery, New York, NY, 7Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 8Hospital for Special Surgey, New York, NY, 9Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Up to 20% of Total Joint Replacement (TJR) patients are dissatisfied, but this is difficult to study as it is challenging to pool data…
  • Abstract Number: 2673 • 2018 ACR/ARHP Annual Meeting

    Different Risk Profiles for Development of Steroid-Related and Steroid-Unrelated Damage in Early Diagnosed SLE: Results from the Italian Multicenter Early Lupus Project Inception Cohort

    Matteo Piga1, Gian Domenico Sebastiani2, Imma Prevete3, Florenzo Iannone4, Laura Coladonato5, Marcello Govoni6, Alessandra Bortoluzzi7, Marta Mosca8, Chiara Tani8, Andrea Doria9, Luca Iaccarino10, Angela Tincani11, Micaela Fredi12, Fabrizio Conti13, Francesca Spinelli14, Mauro Galeazzi15, Francesca Bellisai16, Anna Zanetti17, Greta Carrara18, Carlo Alberto Scirè19 and Alessandro Mathieu1, 1Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, 2Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, 3Azienda Ospedaliera San Camillo of Rome, Roma, Italy, 4Reumatologia Universita e Policlinico di Bari, Bari, Italy, 5Reumatologia, Università e Policlinico di Bari, Bari, Italy, 6UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, 7Section of Rheumatology, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-University Hospital S. Anna, Cona Ferrara, Italy, 8Rheumatology Unit, University of Pisa, Pisa, Italy, 9University and Azienda Ospedaliera of Padova, Padova, Italy, 10Department of Medicine-DIMED, University of Padova, Padova, Italy, 11Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, BRESCIA, Italy, 12Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, 13Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, 14Dipartimento di Medicina Interna e Specialita` Mediche, Sapienza Universita` di Roma, Roma, Italy, 15Rheumatology, University Hospital of Siena, Siena, Italy, 16UOC di Reumatologia, Azienda Ospedaliera Universitaria Senese, Siena, Italy, 17Italian Society for Rheumatology, Milano, Italy, 18Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, 19Italian Society for Rheumatology, Milan, Italy

    Background/Purpose:Preventing organ damage is a major challenge in Systemic Lupus Erythematosus (SLE).To evaluate factors associated with development of steroid-related and unrelated  damage in an inception…
  • Abstract Number: 1438 • 2018 ACR/ARHP Annual Meeting

    Treatment and Response of Down Syndrome Arthropathy

    Jordan T. Jones1, Nasreen Talib2, Daniel J Lovell3 and Mara L Becker4, 1Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, 2General Pediatrics, Children's Mercy Kansas City, Kansas City, MO, 3Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Rheumatology, Children's Mercy Kansas City, Kansas City, MO

    Background/Purpose: Of the very few studies describing Down syndrome arthropathy (DA), crude prevalence estimates indicate DA maybe as common as juvenile idiopathic arthritis (JIA), however,…
  • Abstract Number: 2703 • 2018 ACR/ARHP Annual Meeting

    Delay in Initiation of Therapy Predicts Worse Outcomes in Scleroderma Renal Crisis

    Aditi Patel1, Kinjal Banerjee2 and Soumya Chatterjee3, 1Internal Medicine, Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH, 3Rheumatic and Immunologic Disease, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Scleroderma renal crisis (SRC) is a rare complication of patients with systemic sclerosis (SSc). ACE inhibitors (ACEI) favorably alter the natural history of this…
  • Abstract Number: 1684 • 2018 ACR/ARHP Annual Meeting

    Prolonged Remission/Low Disease Activity State Is Associated with a Better Health-Related Quality

    Manuel Ugarte-Gil1,2, Rocío Gamboa-Cárdenas3, Mariela Medina-Chinchon3, Cristina Reategui-Sokolova3, Francisco Zevallos3, Claudia Elera-Fitzcarrald3,4, Victor R. Pimentel-Quiroz3, Erika Noriega1, Zoila Rodriguez-Bellido3,5, Cesar A. Pastor-Asurza3,5, Graciela S. Alarcón6,7 and Risto Perich-Campos3,5, 1Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 2Rheumatology, Universidad Científica del Sur, Lima, Peru, 3Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 4Universidad Científica del Sur, Lima, Peru, 5Universidad Nacional Mayor de San Marcos, Lima, Peru, 6Universidad Peruana Cayetano Heredia, Lima, Peru, 7Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Achieving remission and low lupus disease activity state (LDAS) in systemic lupus erythematosus (SLE) patients improves their prognosis in terms of damage accrual. But,…
  • Abstract Number: 2707 • 2018 ACR/ARHP Annual Meeting

    Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome

    Nilasha Ghosh1, Xuan Cai2 and Cybele Ghossein3, 1Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Nephrology, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Scleroderma renal crisis (SRC) is the most acute and life-threatening complication of scleroderma characterized by sudden increase in blood pressure and worsening kidney function.…
  • Abstract Number: 1747 • 2018 ACR/ARHP Annual Meeting

    Long-Term Outcomes of Patients with Nonsevere Eosinophilic Granulomatosis with Polyangiitis Given Azathioprine and Glucocorticoids for Remission Induction

    Xavier Puéchal1, Christian Pagnoux2, Gabriel Baron3, François Lifermann4, Loïk Geffray5, Thomas Quémeneur6, Jean-Luc Saraux7, Marie Wislez8, Vincent Cottin9, Marc Ruivard10, Nicolas Limal11, Achille Aouba12, Bernard Bonnotte13, Antoine Neel14, Christian Agard15, Pascal Cohen16, Benjamin Terrier17, Claire Le Jeunne17, Luc Mouthon1, Philippe Ravaud3 and Loïc Guillevin for the French Vasculitis Study Group17, 1Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, 2Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 3Paris Hôtel Dieu, Paris, France, 4Dax, Dax, France, 5Lisieux, Lisieux, France, 6Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, 7Eaubonne, Eaubonne, France, 8Paris Tenon, Paris, Gambia, 9Lyon Louis Pradel, Lyon, France, 10Clermont-Ferrand, Clermont Ferrand, France, 11Créteil Henri Mondor, Créteil, France, 12Caen, Caen, France, 13Dijon, Dijon, France, 14Medecine Interne, Nantes Hôtel Dieu, Nantes, France, 15Nantes Hôtel Dieu, Nantes, France, 16Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 17National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France

    Background/Purpose: At month 24 (M24), CHUSPAN2-trial patients with nonsevere eosinophilic granulomatosis with polyangiitis (EGPA), who received 1 yr of azathioprine (AZA) and glucocorticoids (GC) as…
  • Abstract Number: 2721 • 2018 ACR/ARHP Annual Meeting

    Venous Thromboembolism in ANCA Associated Vasculitis. a Population-Based Cohort Study from Southern Sweden

    Matina Liapi1, David Jayne2, Mårten Segelmark3 and Aladdin Mohammad4, 1Medicine, Blekinge Hospital, Karlskrona, Sweden, 2Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 3Clinical Sciences, Nephrology, Lund University, Lund, Sweden, 4Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden

    Background/Purpose: To estimate the rate and predictors of venous thromboembolic events (VTEs) in a population-based cohort of patients with ANCA- associated vasculitis (AAV). Methods: 322…
  • Abstract Number: 1846 • 2018 ACR/ARHP Annual Meeting

    Menarchal Status at Diagnosis and Final Height in Females with Childhood-Onset Systemic Lupus Erythematosus

    Watchareewan Sontichai1, Daniela Dominguez1, Lawrence Ng1, Deborah M. Levy1, Jonathan Wasserman2, Earl Silverman1 and Linda Hiraki1, 1Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 2Division of Endocrinology, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: The diagnosis of systemic lupus erythematosus (SLE) in childhood affects growth due to disease and therapy. To date, there are few studies of final…
  • Abstract Number: 2779 • 2018 ACR/ARHP Annual Meeting

    Long-Term Outcome and Prognostic Factors after Aortic Valve Surgery Due to Aortic Valve Regurgitation in Patients with Takayasu Arteritis

    So Hye Nam1, Dae-Hee Kim2, Doo-Ho Lim3, Ji Seon Oh1, Seokchan Hong1, Yong-Gil Kim1, Chang Keun Lee1 and Bin Yoo1, 1Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), 2Division of Cardiology, Department of Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), 3Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)

    Background/Purpose: Aortic valve (AV) surgery is often performed for aortic regurgitation (AR) in patients with Takayasu arteritis (TA). However, data on the long-term outcomes, including…
  • Abstract Number: 296 • 2018 ACR/ARHP Annual Meeting

    Does Care By a Multidisciplinary Team Improve Outcomes in Rheumatoid Arthritis? a Randomized Controlled Study

    Manjari Lahiri1,2, Peter P.M. Cheung1,2, Preeti Dhanasekaran2, Su Ren Wong3, Ai Yap3, Daphne Tan3, Amelia Santosa1,2 and Phillip HC Phan2, 1Division of Rheumatology, University Medicine Cluster, National University Hospital, Singapore, Singapore, Singapore, 2Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, 3Department of Rehabilitation, National University Hospital, Singapore, Singapore, Singapore

    Background/Purpose: Quality standards recommend an annual review by a multidisciplinary team (MDT) for all patients with rheumatoid arthritis (RA); however, this is based on expert…
  • Abstract Number: 1850 • 2018 ACR/ARHP Annual Meeting

    A Population Based Study of High School Academic Outcomes in Individuals with Childhood-Onset Chronic Rheumatic Diseases in Manitoba, Canada

    Siok Hoon Lily Lim1,2, Ruth Ann Marrie3, Okechukwu Ekuma4, Marni Brownell4, Christine A. Peschken5, Carol A Hitchon6, Kerstin Gerhold7,8 and Lisa Lix9, 1Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB, Canada, 2Pediatrics, University of MAnitoba, Winnipeg, MB, Canada, 3Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, 4Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, MB, Canada, 5RR 149G, University of Manitoba, Winnipeg, MB, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Pediatrics, University of Manitoba, Winnipeg, MB, Canada, 8Faculty of Health Sciences, Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada, 9Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Childhood-onset chronic rheumatic diseases (ChildCRD) are rheumatic diseases with onset <18 years old, including juvenile arthritis (JA) and systemic autoimmune rheumatic diseases (SARD). ChildCRD…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology